UTI testing market to reach $78.9b by 2036 on antibiotic resistance, diagnostic demand

India and China are emerging as significant centres due ti high investment.

The global urinary tract infection (UTI) testing market is projected to reach $78.9b by 2036, registering a compound annual growth rate of 4.2%, according to a Future Market Insights report.

The report attributes this to the growing prevalence of urinary tract infections, rising concerns of antibiotic resistance, and increasing adoption of point-of-care and molecular diagnostic technologies.

Dipstick tests continue to dominate routine screening applications due to their affordability, ease of use, and compatibility with primary care workflows.

Meanwhile, molecular diagnostic technologies are gaining momentum as healthcare providers seek enhanced sensitivity, specificity, and rapid clinical decision support.

North America and Europe continue to lead the market due to established healthcare infrastructure, reimbursement support, and antimicrobial stewardship initiatives.

Meanwhile, Asia Pacific markets are experiencing accelerated growth as governments expand healthcare access, improve laboratory infrastructure, and promote diagnostic modernisation programmes.

India and China are emerging as significant growth centres due to increasing healthcare investments, rising awareness of infectious disease management, and expanding primary care testing capabilities.